Atlas Trials

Vir Biotechnology, Inc.

23 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Vir Biotechnology, Inc.

RecordFirmDate
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection (NCT07142811)Vir Biotechnology, Inc.2025-08-05
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (NCT07128550)Vir Biotechnology, Inc.2025-07-30
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT06960395)Vir Biotechnology, Inc.2025-07-22
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (NCT06903338)Vir Biotechnology, Inc.2025-03-12
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (NCT05612581)Vir Biotechnology, Inc.2023-05-10
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A (NCT05567783)Vir Biotechnology, Inc.2022-10-30
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 (NCT05484206)Vir Biotechnology, Inc.2022-09-21
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (NCT05461170)Vir Biotechnology, Inc.2022-09-17
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (NCT05356741)Vir Biotechnology, Inc.2022-04-13
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) (NCT05280717)Vir Biotechnology, Inc.2022-03-28
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (NCT04856085)Vir Biotechnology, Inc.2021-07-11
A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants (NCT04988152)Vir Biotechnology, Inc.2021-07-06
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. (NCT04913675)Vir Biotechnology, Inc.2021-06-10
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (NCT04779879)Vir Biotechnology, Inc.2021-02-18
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers (NCT04725877)Vir Biotechnology, Inc.2020-12-28
VIR-7831 for the Early Treatment of COVID-19 in Outpatients (NCT04545060)Vir Biotechnology, Inc.2020-08-27
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection (NCT04412863)Vir Biotechnology, Inc.2020-07-03
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection (NCT04423393)Vir Biotechnology, Inc.2020-05-26
Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B (NCT03672188)Vir Biotechnology, Inc.2018-11-14

Track Vir Biotechnology, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.